Glucocorticoids Reduce Aberrant O-Glycosylation of IgA1 in IgA Nephropathy Patients
Open Access
- 6 March 2018
- journal article
- research article
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 43 (2) , 350-359
Abstract
Background/Aims: IgA nephropathy is associated with aberrant O-glycosylation of IgA1, which is recognized by autoantibodies leading to the formation of circulating immune complexes. Some of them, after deposition into kidney mesangium, trigger glomerular injury. In patients with active disease nonresponding to angiotensin-converting enzyme inhibitors or angiotensin II blockers, corticosteroids are recommended. Methods: The relationship between the corticosteroid therapy and serum levels of IgA, aberrantly O-glycosylated IgA1, IgA-containing immune complexes and their mesangioproliferative activity was analyzed in IgA nephropathy patients and disease and healthy controls. Results: Prednisone therapy significantly reduced proteinuria and levels of serum IgA, galactose-deficient IgA1, and IgA-IgG immune complexes in IgA nephropathy patients and thus reduced differences in all of the above parameters between IgAN patients and control groups. A moderate but not significant reduction of mesangioproliferative potential of IgA-IgG immune complexes and IgA sialylation was detected. Conclusion: The prednisone therapy reduces overall aberrancy in IgA1 O-glycosylation in IgA nephropathy patients, but the measurement of IgA1 parameters does not allow us to predict the prednisone therapy outcome in individual patients.Keywords
This publication has 38 references indexed in Scilit:
- The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progressionKidney International, 2012
- IgA1 immune complexes from pediatric patients with IgA nephropathy activate cultured human mesangial cellsNephrology Dialysis Transplantation, 2011
- IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1Journal of Clinical Investigation, 2008
- Identification and Characterization of CMP-NeuAc:GalNAc-IgA1 α2,6-Sialyltransferase in IgA1-producing CellsJournal of Molecular Biology, 2007
- Clinical Trial to Evaluate Omega-3 Fatty Acids and Alternate Day Prednisone in Patients with IgA NephropathyClinical Journal of the American Society of Nephrology, 2006
- IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cellsKidney International, 2005
- Interactions of human mesangial cells with IgA and IgA-containing immune complexes1Kidney International, 2002
- Cloning and Expression of Human Core 1 β1,3-GalactosyltransferaseJournal of Biological Chemistry, 2002
- Circulating immune complexes and immunoglobulin A rheumatoid factor in patients with mesangial immunoglobulin A nephropathies.Journal of Clinical Investigation, 1986
- Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus.Journal of Clinical Investigation, 1980